Data for the detection and monitoring of key predictive biomarkers for patients with newly diagnosed or progressing metastatic lung cancer on therapy to be presented at the Association for Molecular Pathology Annual Meeting SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc.
SAN DIEGO , Oct. 29, 2015 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announces that it will release financial results for the quarter ended September
SAN DIEGO , Oct. 14, 2015 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the 2015 Aegis
More than 99 million healthcare consumers now have access to Biocept's suite of blood-based diagnostics through healthcare payors and plans SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
Increases coverage to approximately 31 million PPO members SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing assays for liquid biopsies to improve the detection and treatment of cancer, announces additional agreements with
Fifth issued U.S. patent covers the use of antibodies in the capture and detection of rare cells from biological fluids with Biocept's microchannel capture device SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC) , a molecular diagnostics company commercializing and developing liquid
Clinical Data Shows Assay's Utility in Therapeutic Management of Patients with Non-Small Cell Lung Cancer SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer,
Detection of ALK biomarker expression in circulating tumor cells could provide a new method to identify and monitor patients with ALK+ lung cancer SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing biomarkers in liquid biopsies
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, announces that President and CEO Michael Nall is scheduled to present a corporate overview at the Rodman &
